The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Cellular Phenotyping in Human iPSCS from the PPMI Cohort, 2022Defining Mechanisms in Different Brain Cells that Drive Progression in Parkinson’s Disease
Study Rationale: The death of dopamine-producing neurons is the defining feature of Parkinson’s disease (PD), leading to the motor symptoms characteristic of the disorder. Given this obvious...
-
Research Grant, 2022Assessing the Aggregation of Alpha-synuclein in the Gastrointestinal Tract
Study Rationale: A growing body of evidence suggests that Parkinson’s disease (PD) may begin in the stomach or elsewhere along the gastrointestinal (GI) tract before spreading to the brain. If this...
-
Research Grant, 2022Cognitive Assessment of Non-Human Primate Models of Parkinson's Disease
Study Rationale: Cognitive impairments cause significant disability for people with Parkinson’s disease (PD). Problems such as reduced attention or difficulty following plans can occur very early in...
-
Translational Pipeline Program, 2022Investigating GPR55 as a Novel Neuroprotective Target in Preclinical Models of Parkinson’s Disease
Study Rationale: Cannabinoids — substances derived from the cannabis plant — have demonstrated neuroprotective properties useful for the treatment of neurodegenerative disorders. Although these...
-
Novel PET Tracer Development Program, 2022Screening for PET Tracers that will Bind to the P2Y12 Receptor and Allow Monitoring of Microglia Activation During Neuroinflammation
Study Rationale: One of the hallmarks of Parkinson’s disease (PD) is neuroinflammation. During this dynamic process, the brain’s immune cells, called microglia, become activated and can either prolong...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2022Glucocerebrosidase Activation as a Therapeutic Strategy for Parkinson’s Disease
Study Rationale: Mutations in GBA1, the gene that encodes glucocerebrosidase (GCase), diminish GCase activity in an estimated 7 to 10% of people with Parkinson’s disease (PD). In addition, reduced...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.